Drugs Xagena
The FDA ( U.S. Food and Drug Administration ) has approved the reintroduction of Tysabri ( Natalizumab ) as a monotherapy treatment for relapsing forms of multiple sclerosis to slow the progression of ...
Researchers have completed an extensive study of more than 3,000 patients who received a Natalizumab ( Tysabri ), that was linked to three cases of a serious brain infection in large clinical trials h ...
The FDA ( Food and Drug Administration ) has approved Tysabri ( Natalizumab ) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequa ...
Biogen ldec and Elan have informed HealthCare Profesionals of new safety information regarding Tysabri ( Natalizumab ). The full Prescribing Information has been revised to add to the Warnings and P ...
At the end of July 2008, two cases of progressive multifocal leukoencephalopathy ( PML ) were reported in patients with multiple sclerosis receiving Natalizumab ( Tysabri ) in the European post-market ...
The Committee of Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending approval of a variation to the marketing authorization o ...
